PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-27.70%
G&A reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
1234.83%
Other expenses growth while AXSM reduces costs. John Neff would investigate differences.
115.67%
Operating expenses growth above 1.5x AXSM's 6.62%. Michael Burry would check for inefficiency.
115.67%
Total costs growth above 1.5x AXSM's 8.31%. Michael Burry would check for inefficiency.
719.71%
Interest expense growth above 1.5x AXSM's 24.56%. Michael Burry would check for over-leverage.
No Data
No Data available this quarter, please select a different quarter.
-115.67%
EBITDA decline while AXSM shows 35.57% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-115.67%
Operating income decline while AXSM shows 35.57% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
115.67%
Other expenses growth while AXSM reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
133.51%
Tax expense change of 133.51% while AXSM maintains burden. Bruce Berkowitz would investigate strategy.
-133.51%
Net income decline while AXSM shows 19.26% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-132.80%
EPS decline while AXSM shows 20.49% growth. Joel Greenblatt would examine position.
-132.80%
Diluted EPS decline while AXSM shows 20.49% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.